Healios KK
Business Services · Japan · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Hibiya Mitsui Tower 12 Floor Work Stylin...Phone Number
+81 357778308Website
www.healios.co.jpRevenue
<$5 MillionStock Symbol
4593Industry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Healios KK
Healios is a Tokyo-listed clinical-stage biotechnology company established in 2011, recognized as a pioneer in regenerative medicine in Japan. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome. Healios has been listed on the Tokyo Stock Exchange since 2015.Explore more
Healios KK Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Healios KK your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Healios KK, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Healios KK had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Healios KK has new funding data
Congratulate Masked Content for being promoted to Masked Content at Healios KK
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Healios KK recently announced quarterly report
Check out if Healios KK is spiking on competitors!
Product Launch: Get notified when Healios KK launches new products
Check if Healios KK has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Healios KK as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Healios KK is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Healios KK is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Healios KK.
Healios KK Tech Stack
A closer look at the technologies used by Healios KK
Most Recent Scoops
Project
Healios KK is launching clinical trial sites for its ARDS treatment study in Japan first, then expanding to the U.S., Korea, Taiwan, and some European sites. The company's primary endpoint for ARDS is mortality-adjusted ventilator-free days, with secondary endpoints including all-cause mortality.
Medical Research, Pharmaceuticals, Clinical Operations
Project
plans to commercialize its ARDS treatment in Japan while running a global study. The company's 3D bioreactor manufacturing platform allows production of hundreds of thousands of doses from a single donor, providing a significant advantage in product scalability.
Product Development, Pharmaceuticals, Manufacturing Operations
Project
Healios KK is leveraging the favorable Japanese regulatory framework for cell therapy to rapidly advance its products to markets. The company is focusing on filing for conditional approval for ARDS in Japan, launching a global phase three study called Revive ARDS for approval in the U.S. and Europe, and generating cash from the sale of Culture Super Natan, a byproduct from its manufacturing process.
Product Development, Medical Research, Pharmaceuticals
Project
plans to handle sales of its ARDS treatment in Japan independently. For U.S. commercialization, the company may consider partnerships after the interim analysis of 300 patients in the global study.
Partnership, Sales, Pharmaceuticals
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Healios KK News & Media
Healios K.K. to Present at Jefferies Global Healthcare Conference
NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) -- HEALIOS K.K. (“Healios”) is pleased to announce that Richard Kincaid, Chief Financial Officer, will present at the Jefferies Global Healthcare Conference in London as follows:Healios K.K. to Present at Chardan’s 9th Annual Genetic Medicines Conference
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HEALIOS K.K. (“Healios”) is pleased to announce that Richard Kincaid, Chief Financial Officer, will present at the Chardan 9th Annual Genetic Medicines Conference in New York City as follows:Healios K.K. to Present at the 2025 Jefferies Global Healthcare Conference
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- HEALIOS K.K. (“Healios”) is pleased to announce that Richard Kincaid, Chief Financial Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows:Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. (“Healios”) under the acute respiratory distr
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Healios KK
Sign Up For FreeTo access detailed company insights
Healios is a Tokyo-listed clinical-stage biotechnology company established in 2011, recognized as a pioneer in regenerative medicine in Japan. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, isch... Read More
